Bioventus said today it entered the Taiwanese patient care market with the launch of its Durolane single-injection joint-fluid osteoarthritis treatment. The treatment is based around the NASHA process which produces stabilized hyaluronic acid which provides lubrication and cushioning in a normal joint. “The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus […]
Bioventus said it acquired BioStructures, a developer of absorbable bone grafts, for an undisclosed amount. The deal for Newport Beach, Calif.-based BioStructures covers its entire line of products, including the Interface bioactive bonegraft and Signafuse bioactive bonegraft putty, plus its R&D pipeline; BioStructures employees will be given offers at Bioventus, which is based in Durham, N.C. Created in […]
Cook said yesterday that Cook Medical president Pete Yonkman will become the new president of Cook Group Inc., as current president Kem Hawkins is slated to retire on July 1. “Under Kem’s leadership, we have seen exciting new opportunities to help patients, our employees, and the communities where we operate. With his guidance, our company […]
October 10, 2014 by Brad Perriello
Bioventus said it acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount.
OsteoAMP is a tissue-based product used to promote natural bone growth and healing in the spine, according to a press release.
Mindray Medical (NYSE:MR) chief Li Xiting will share the corner office, so to speak, with new co-CEO Cheng Minghe, who takes the new title in addition to continuing as the company’s chief strategic officer.
Cheng is one of the founders of the Shenzhen, China-based company, and has worked in various roles since 1991.
MRI Interventions (OTC:MRIC), a company developing minimally invasive neurosurgery systems, launched an initial public offering with shares at $1 apiece.
The Memphis-based company’s flagship ClearPoint technology allows patients to undergo surgery during MRI scanning, using the images to target areas of the brain for surgery.
British orthopedic titan Smith & Nephew (NYSE:SNN) shuffled its business deck yet again with the spinout of its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands.
Essex will own 51% of the new business, named Bioventus LLC, with Smith & Nephew holding the remainder.
SNN will also get $98 million in cash, which it plans to use to pay down debt, and a $160 million, 5-year note from Bioventus, according to a press release.